Vanguard Global Advisers
INDV icon

Vanguard Global Advisers’s Indivior Pharmaceuticals INDV Stock Holding History

Vanguard Global Advisers’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Sell
53,516
-3,747
-7% -$136K ﹤0.01% 1192
2026
Q1 		$1.75M Buy
+57,263
New +$1.89M ﹤0.01% 1286

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's INDV Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Indivior Pharmaceuticals (INDV) stake by 6.5% in Q2 2026, selling an estimated $136K and leaving 53,516 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Vanguard Global Advisers first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Vanguard Global Advisers held 53,516 shares of Indivior Pharmaceuticals worth $2.2M as of Q2 2026.
  • Vanguard Global Advisers sold 3,747 Indivior Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1192 holding.
  • Vanguard Global Advisers first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.